Cannabinoid pharmacology: the first 66 years

By R. Pertwee. British Journal of Pharmacology, 2006

702 citations recorded by the source corpus.

Subfields: Cellular and Molecular Neuroscience, Clinical Psychology, Pharmacology

View Paper: https://www.semanticscholar.org/paper/631a5be656205e63072bc1422bf91a8b8334cefb

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cellular and Molecular Neuroscience

1. V. Di Marzo
2. U. Kumar
3. Shenglong Zou
4. Marilyn Huestis
5. Nathalie A. Desrosiers
6. D. Gorelick
7. M. Castaneto
8. R. Hartman

In Clinical Psychology

1. V. Di Marzo
2. Marilyn Huestis
3. Nathalie A. Desrosiers
4. D. Gorelick
5. M. Castaneto
6. R. Hartman
7. Sandrine Pirard
8. U. Kumar

In Pharmacology

1. U. Kumar
2. Shenglong Zou
3. V. Di Marzo
4. O. Kayser
5. P. Kusari
6. Marilyn Huestis
7. Nathalie A. Desrosiers
8. D. Gorelick

Citations in the corpus

• Targeting the endocannabinoid system: to enhance or reduce? (2008, background): “These targets include the G-protein-coupled cannabinoid receptors and their endogenous ligands, the endocannabinoids”
• Endophytic fungi harbored in Cannabis sativa L.: diversity and potential as biocontrol agents against host plant-specific phytopathogens (2013, background): “Although Δ9-tetrahydrocannabinol (Δ9-THC) is considered to be the major psychoactive compound (Pertwee 2006; Sirikantaramas et al. 2005; Taura et al. 1995), there is still a lot of intensive investigation to verify if pure cannabinoids provide better therapeutic effect over the whole plant…”
• Synthetic Cannabinoids: Epidemiology, Pharmacodynamics, and Clinical Implications (2014, methodology): “SC were developed as research tools to explore the endocannabinoid system and as potential therapeutics (Pertwee, 2006).”
• The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9‐tetrahydrocannabinol, cannabidiol and Δ9‐tetrahydrocannabivarin (2008, background): “Among the effects that D9-THC seems to produce in vivo in healthy animals by activating neuronal CB1 receptors are several that are frequently used as measured responses in bioassays for CB1 receptor agonists (reviewed in Howlett et al., 2002; Pertwee, 2006).”
• Cannabinoid Receptors and the Endocannabinoid System: Signaling and Function in the Central Nervous System (2018, background): “However, following the discovery of THC and subsequent emerging of several chemically synthesized cannabinoids, the successful mapping and the pharmacological characterization of cannabinoid binding sites in the brain revealed the existence of a putative CBR and its similarity to GPCR nature, which ”